J
James D. Brien
Researcher at Saint Louis University
Publications - 93
Citations - 4063
James D. Brien is an academic researcher from Saint Louis University. The author has contributed to research in topics: Dengue virus & Flavivirus. The author has an hindex of 29, co-authored 80 publications receiving 3268 citations. Previous affiliations of James D. Brien include University of Massachusetts Medical School & University of Massachusetts Amherst.
Papers
More filters
Journal ArticleDOI
Development of a Highly Protective Combination Monoclonal Antibody Therapy against Chikungunya Virus
Pankaj Pal,Kimberly A. Dowd,James D. Brien,Melissa A. Edeling,Sergey Gorlatov,Syd Johnson,Iris Lee,Wataru Akahata,Gary J. Nabel,Mareike K. S. Richter,Jolanda M. Smit,Daved H. Fremont,Theodore C. Pierson,Mark T. Heise,Michael S. Diamond +14 more
TL;DR: Administration of a single dose of a combination of two neutralizing MAbs limited the development of resistance and protected immunocompromised mice against disease when given 24 to 36 hours before CHIKV-induced death.
Journal ArticleDOI
The development of therapeutic antibodies that neutralize homologous and heterologous genotypes of dengue virus type 1
Bimmi Shrestha,James D. Brien,Soila Sukupolvi-Petty,S. Kyle Austin,Melissa A. Edeling,Taekyung Kim,Katie M. O'Brien,Christopher A. Nelson,Syd Johnson,Daved H. Fremont,Michael S. Diamond +10 more
TL;DR: A complex structural epitope on DIII of DENV-1 that can be recognized by protective antibodies with therapeutic potential is defined and sequence variation in DIII alone failed to explain disparities in neutralizing potential of MAbs among different genotypes.
Journal ArticleDOI
Structure and function analysis of therapeutic monoclonal antibodies against dengue virus type 2.
Soila Sukupolvi-Petty,S. Kyle Austin,Michael Engle,James D. Brien,Kimberly A. Dowd,Katherine L. Williams,Syd Johnson,Rebeca Rico-Hesse,Eva Harris,Theodore C. Pierson,Daved H. Fremont,Michael S. Diamond +11 more
TL;DR: Overall, these studies define the structural and functional complexity of antibodies against DENV-2 with protective potential.
Journal ArticleDOI
Zika virus pathogenesis in rhesus macaques is unaffected by pre-existing immunity to dengue virus
Petraleigh Pantoja,Erick X. Pérez-Guzmán,Idia V. Rodríguez,Laura J. White,Olga González,Crisanta Serrano,Luis D. Giavedoni,Vida L. Hodara,Lorna Cruz,Teresa Arana,Melween I. Martínez,Mariah Hassert,James D. Brien,Amelia K. Pinto,Aravinda M. de Silva,Carlos A. Sariol +15 more
TL;DR: The results, while confirming ADE in vitro, suggest that pre-existing DENV immunity does not result in more severe ZIKV disease and that the previous exposure to DENV may result in modulation of the immune response without resulting in enhancement of ZikV pathogenesis.
Journal ArticleDOI
Preliminary aggregate safety and immunogenicity results from three trials of a purified inactivated Zika virus vaccine candidate: phase 1, randomised, double-blind, placebo-controlled clinical trials.
Kayvon Modjarrad,Leyi Lin,Sarah L. George,Sarah L. George,Kathryn E. Stephenson,Kathryn E. Stephenson,Kenneth H. Eckels,Rafael De La Barrera,Richard G. Jarman,Erica L Sondergaard,Janice Tennant,Jessica L Ansel,Kristin Mills,Michael Koren,Merlin L. Robb,Jill Barrett,Jason Thompson,Alison E Kosel,Peter Dawson,Andrew J. Hale,C Sabrina Tan,Stephen R. Walsh,Keith Meyer,James D. Brien,Trevor A Crowell,Azra Blazevic,Karla Mosby,Rafael A. Larocca,Peter Abbink,Michael R. Boyd,Christine A. Bricault,Michael S. Seaman,Anne Basil,Melissa Walsh,Veronica Tonwe,Daniel F. Hoft,Daniel F. Hoft,Stephen J. Thomas,Dan H. Barouch,Dan H. Barouch,Nelson L. Michael +40 more
TL;DR: The ZPIV candidate was well tolerated and elicited robust neutralising antibody titres in healthy adults, with peak geometric mean titres seen at day 43 and exceeding protective thresholds seen in animal studies.